Overview

Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study

Status:
Active, not recruiting

Trial end date:
2022-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to see what effects, good and/or bad, the combination of ixazomib and dexamethasone has on the patient and the smoldering multiple myeloma.

Phase:

Phase 1

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Collaborator:

Millennium Pharmaceuticals, Inc.

Treatments:

BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Glycine
Ixazomib